Drug-Resistant Mold Infections Spreading In U.S. Hospitals: Study

Researchers warn that drug-resistant mold is proliferating in the environment, is leading to more hard-to-treat fungal infections being seen in hospitals

An increasing number of patients are being treated for drug-resistant mold infections in hospitals, according to the findings of a new study, which suggest that many of the patients are becoming infected from the environment.

In a report published last month in the medical journal Nature Microbiology, U.K. researchers indicated that that nearly 75% of patients tested positive for drug-resistant molds and many of the patients were infected from sources like the soil or the air before winding up in the hospital with difficult to treat fungal infections.

Researchers from the School of Public Health at Imperial College London analyzed the DNA of 218 samples of Aspergillus fumigates from England, Wales, Scotland and Ireland between 2005 and 2017. Overall, 7 in 10 samples of drug-resistant mold were from infected people, but the other samples were from the environment, including soil, compost, plant bulbs, the air and other sources.

Researchers found six strains of A. fumigatus that spread from the environment and infected six patients.

Among the 218 samples, half were resistant to at least one first-line anti-fungal drug, 48% were resistant to itraconazole, 29% to voriconazole, and 21% to posaconazole. More than 10% of human samples were resistant to two or more anti-fungal drugs and 23 environmental samples were resistant to anti-fungal drugs.

Infections caused by the fungal pathogen Aspergillus fumigatus are increasingly resistant to anti-fungal drugs, which were once was the first line treatment for mold infections. This mold causes a lung infection called aspergillosis in those who suffer from lung conditions or weakened immune systems.

Drug resistant mold is increasingly found in the environment and can infect the lungs when people inhale spores while working in the dirt, planting gardens or simply from air sources, the researchers warned. Drug resistance due to widespread agricultural use of azole fungicides is the primary cause, which are similar to azole drugs used to treat aspergillosis.

In the 218 samples tested, 50 new genes were linked with drug resistance and five new combinations of DNA changes were linked with drug resistance including one resistant to multiple drugs.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

The rates of drug resistant aspergillosis have grown significantly from negligible levels before 1999 to levels reaching 40% in Europe in recent years.

In addition, more people are receiving stem cell therapy, solid organ transplants or immunosuppressive therapy which makes them more resistant to anti-fungal medications which can put them at greater risk if they are infected with the mold.

Aspergillosis affects 10 to 20 million people worldwide. Including other fungal infections, more than a billion people are infected with mold worldwide. Fungal infections carry a death rate that matches malaria or tuberculosis.

Researchers concluded there is a greater need to monitor the environment for A. fumigatus and hot spots to help patients understand the risk it poses.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits
Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits (Posted yesterday)

A federal judge has agreed to divide lawsuits over gastroparesis injuries linked to drugs like Ozempic and Mounjaro into multiple phases, examining how the condition is diagnosed and whether plaintiffs' claims are preempted by federal laws.

Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn
Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn (Posted 2 days ago)

Lawsuit alleges that Abbott Laboratories failed to provide families and the medical community with adequate warnings about the risks associated with it’s cow’s milk-based Similac formula, which a now adult woman indicates has left her with life-long NEC injuries.

Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects
Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects (Posted 3 days ago)

Six breast cancer patients have asked a federal judge for permission to amend a complaint filed in March 2024, which describes problems linked to the device and painful side effects experienced when the tissue marker migrated out of position or shattered inside their bodies.